Nicole Doria-Rose, Ph.D.

Stadtman Investigator

Antibody Immunity Section

NIAID/VRC

View Site

Building 40, Room 5509
40 Convent Drive
Bethesda, MD 20892

301-761-5279

doriarosen@mail.nih.gov

Research Topics

The aims of AIMS are:

  • To understand pathways of HIV broadly neutralizing antibody (bNAb) development and co-evolution with virus
  • To design and test HIV Vaccines inspired by antibody-virus co-evolution studies
  • To discover and characterize new HIV bNAbs with potential clinical use

Neutralizing antibodies, which block virus infection, are critical components of effective immune responses and the correlate of protection for many licensed vaccines. Broadly neutralizing antibodies (bNAbs) against HIV are able to recognize diverse HIV strains from around the world; eliciting bNAbs will be a crucial function of a protective vaccine. While no candidate HIV vaccine has yet succeeded in eliciting bNAbs, a fraction of people living with HIV develop them naturally. We are studying these cases to understand the way the bNAbs target HIV and how they develop over time. We previously showed that viral escape mutants drive the development of breadth in antibodies targeting the apex of the HIV Envelope protein (the viral “spike”), and identified key early changes in bNAbs targeting the HIV Env membrane-proximal external region. Work continues to understand virus-antibody co-evolution for these and other targets on HIV Env. These studies provide a blueprint for vaccine design as we strive to elicit bNAbs. Along the way, we are identifying highly potent bNAbs that may be useful as drugs for HIV prevention, treatment, and cure.

Biography

Nicole Doria-Rose earned her PhD from Cornell University in 1998, studying retrovirus assembly. She then trained in HIV immunology during her post-doctoral work at the Seattle Biomedical Research Institute. In 2006 she joined the National Institute of Allergy and Infectious Diseases and became a Staff Scientist at the Vaccine Research Center in 2011. She is now Chief of the Antibody Immunity Section and an Earl Stadtman Tenure-Track Investigator at the VRC.

Dr. Doria-Rose has led pioneering research on the interplay of evolving virus populations and maturing antibody responses in people living with HIV. This work has provided templates for vaccine candidates and led to the development of monoclonal antibodies that have been tested in clinical trials for HIV prevention. Her contributions have earned her multiple NIH Director's Awards and NIAID Merit Awards.

Selected Publications

  1. Cheng J, Cale EM, Maghsoudi A, Sutton MS, Longo NS, Gillespie RA, Wang L, Kosik I, Chong S, Yasuhara A, Bylund T, Schön A, Tripathi P, Tsybovsky Y, Lei H, Morano NC, Lupatkin AB, Morton AJ, Lang ZC, Becker JE, Frascilla IR, Lee M, Li N, Liu C, Roark RS, Shen CH, Teng IT, Van Wazer DJ, Wang D, Wu L, Ahlsen G, Castro M, Du H, Ernandes MJ, Li T, Lin BC, Louder MK, McKee K, Merriam JS, O'Dell S, Ou L, Pletnev S, Prikryl D, Qiu Q, Rubin S, Sastry M, Schmidt SD, Shajahan A, Shiakolas AR, Srivatsan S, Zhang B, Zhou Q, Connors M, Gall JG, Guo Y, Huang RK, Huang Y, Koup RA, Lei QP, Mascola JR, Rawi R, Serebryannyy L, Shapiro L, Sheng Z, Ho DD, Wilson PC, Yewdell JW, Pierson TC, Kanekiyo M, Doria-Rose NA, Kwong PD, Zhou T. Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields. Adv Sci (Weinh). 2026:e77172.
  2. Zhang B, Gollapudi D, Gorman J, O'Dell S, Damron LF, McKee K, Asokan M, Yang ES, Pegu A, Lin BC, Chao CW, Chen X, Gama L, Ivleva VB, Law WH, Liu C, Louder MK, Schmidt SD, Shen CH, Shi W, Stein JA, Seaman MS, McDermott AB, Carlton K, Mascola JR, Kwong PD, Lei QP, Doria-Rose NA. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. Sci Rep. 2022;12(1):17876.
  3. Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES, mRNA-1273 Study Group§, Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA, Arega J, Beigel JH, Buchanan W, Elsafy M, Hoang B, Lampley R, Kolhekar A, Koo H, Luke C, Makhene M, Nayak S, Pikaart-Tautges R, Roberts PC, Russell J, Sindall E, Albert J, Kunwar P, Makowski M, Anderson EJ, Bechnak A, Bower M, Camacho-Gonzalez AF, Collins M, Drobeniuc A, Edara VV, Edupuganti S, Floyd K, Gibson T, Ackerley CMG, Johnson B, Kamidani S, Kao C, Kelley C, Lai L, Macenczak H, McCullough MP, Peters E, Phadke VK, Rebolledo PA, Rostad CA, Rouphael N, Scherer E, Sherman A, Stephens K, Suthar MS, Teherani M, Traenkner J, Winston J, Yildirim I, Barr L, Benoit J, Carste B, Choe J, Dunstan M, Erolin R, Ffitch J, Fields C, Jackson LA, Kiniry E, Lasicka S, Lee S, Nguyen M, Pimienta S, Suyehira J, Witte M, Bennett H, Altaras NE, Carfi A, Hurley M, Leav B, Pajon R, Sun W, Zaks T, Coler RN, Larsen SE, Neuzil KM, Lindesmith LC, Martinez DR, Munt J, Mallory M, Edwards C, Baric RS, Berkowitz NM, Boritz EA, Carlton K, Corbett KS, Costner P, Creanga A, Doria-Rose NA, Douek DC, Flach B, Gaudinski M, Gordon I, Graham BS, Holman L, Ledgerwood JE, Leung K, Lin BC, Louder MK, Mascola JR, McDermott AB, Morabito KM, Novik L, O'Connell S, O'Dell S, Padilla M, Pegu A, Schmidt SD, Shi W, Swanson PA 2nd, Talana CA, Wang L, Widge AT, Yang ES, Zhang Y, Chappell JD, Denison MR, Hughes T, Lu X, Pruijssers AJ, Stevens LJ, Posavad CM, Gale M Jr, Menachery V, Shi PY. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372-1377.
  4. Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity. 2019;50(3):677-691.e13.
  5. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55-62.

Related Scientific Focus Areas

This page was last updated on Saturday, August 29, 2026